REC-7735
Solid tumors
REC-7735 is a PI3Kα H1047R mutant selective inhibitor being developed for the treatment of solid tumors including HER2- HR+ breast cancer where the PI3Kα-H1047R mutation is present. This highly selective inhibitor targets the most frequent PIK3CA mutation and a key driver of cancer. REC-7735 was designed to maximize the therapeutic window and to avoid dose-limiting hyperglycemia or other off-target AEs associated with wild-type PI3Kα inhibition. Preclinical models have shown tumor regression when used as a monotherapy treatment and when combined with standard of care.
*Annual incidence of metastatic PIK3CA-H1047R mutated patients with breast, endometrial, ovarian, and colorectal cancer. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
Case study
The challenge:
1
2
The unique how:
The outcome:
Learn more about clinical trial at Recursion.
Clinical trials
